ATE374030T1 - Kombination eines mglur2 antagonists und eines ache inhibitors zur behandlung von akuten und/oder chronischen neurologischen krankheiten - Google Patents

Kombination eines mglur2 antagonists und eines ache inhibitors zur behandlung von akuten und/oder chronischen neurologischen krankheiten

Info

Publication number
ATE374030T1
ATE374030T1 AT04741126T AT04741126T ATE374030T1 AT E374030 T1 ATE374030 T1 AT E374030T1 AT 04741126 T AT04741126 T AT 04741126T AT 04741126 T AT04741126 T AT 04741126T AT E374030 T1 ATE374030 T1 AT E374030T1
Authority
AT
Austria
Prior art keywords
acute
treatment
combination
neurological diseases
chronic neurological
Prior art date
Application number
AT04741126T
Other languages
English (en)
Inventor
Theresa Ballard
Mcarthur Silvia Gatti
Erwin Goetschi
Juergen Wichmann
Thomas Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34130033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE374030(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE374030T1 publication Critical patent/ATE374030T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04741126T 2003-07-25 2004-07-17 Kombination eines mglur2 antagonists und eines ache inhibitors zur behandlung von akuten und/oder chronischen neurologischen krankheiten ATE374030T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03016968 2003-07-25

Publications (1)

Publication Number Publication Date
ATE374030T1 true ATE374030T1 (de) 2007-10-15

Family

ID=34130033

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04741126T ATE374030T1 (de) 2003-07-25 2004-07-17 Kombination eines mglur2 antagonists und eines ache inhibitors zur behandlung von akuten und/oder chronischen neurologischen krankheiten

Country Status (27)

Country Link
US (1) US7235547B2 (de)
EP (1) EP1651234B1 (de)
JP (1) JP5005343B2 (de)
KR (1) KR100764330B1 (de)
CN (1) CN1856312A (de)
AR (1) AR045926A1 (de)
AT (1) ATE374030T1 (de)
AU (1) AU2004262897B9 (de)
BR (1) BRPI0412919A (de)
CA (1) CA2532347C (de)
CO (1) CO5640124A2 (de)
DE (1) DE602004009195T2 (de)
DK (1) DK1651234T3 (de)
ES (1) ES2293287T3 (de)
HR (1) HRP20070552T3 (de)
IL (1) IL173131A (de)
MX (1) MXPA06000705A (de)
MY (1) MY138394A (de)
NO (1) NO20060328L (de)
NZ (1) NZ544719A (de)
PL (1) PL1651234T3 (de)
PT (1) PT1651234E (de)
RU (1) RU2357734C2 (de)
SI (1) SI1651234T1 (de)
TW (1) TW200524614A (de)
WO (1) WO2005014002A1 (de)
ZA (1) ZA200600693B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050222175A1 (en) * 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7612078B2 (en) * 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7488736B2 (en) * 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7576211B2 (en) * 2004-09-30 2009-08-18 Epix Delaware, Inc. Synthesis of thienopyridinone compounds and related intermediates
US7598265B2 (en) * 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
US7407966B2 (en) * 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
EP2275096A3 (de) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenese durch modulation des Muscarinrezeptors
EP2258357A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (de) 2005-10-31 2011-04-27 Braincells, Inc. Gaba-rezeptor-vermittelte modulation von neurogenese
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (de) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenese mittels angiotensin-modulation
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
WO2010065743A2 (en) * 2008-12-03 2010-06-10 Nanotherapeutics, Inc. Bicyclic compounds and methods of making and using same
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8541404B2 (en) * 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
RU2472475C2 (ru) * 2010-04-20 2013-01-20 Учреждение образования "Белорусский государственный медицинский университет" (УО БГМУ) Способ комбинированного лечения глаукомной оптической нейропатии
HK1206615A1 (en) 2012-10-23 2016-01-15 霍夫曼-拉罗奇有限公司 Mglu2/3 antagonists for the treatment of autistic disorders
MX2016013711A (es) 2014-04-23 2017-01-13 Hoffmann La Roche Antagonistas de receptores de glumato metabotropicos 2/3 (mglu2/3) para el tratamiento de varias discapacidades intelectuales.
CN112462047B (zh) * 2020-11-13 2023-02-07 北京元恩生物技术有限公司 一种尼卡巴嗪检测试剂盒及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
DE69911603T2 (de) * 1998-06-22 2004-07-29 Neurosearch A/S Synthese von 5- oder 8-bromoisoquinolin derivaten
US6194403B1 (en) * 1999-09-09 2001-02-27 Unitech Pharmaceuticals, Inc. Tacrine derivatives for treating Alzheimer's disease
TR200201023T2 (tr) * 1999-10-15 2002-09-23 F. Hoffmann-La Roche Ag Benzodiazepin türevleri.
AU779874B2 (en) * 1999-10-15 2005-02-17 F. Hoffmann-La Roche Ag Benzodiazepine derivatives
CA2310926C (en) * 2000-04-03 2002-10-15 Janssen Pharmaceutica N.V. A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
EP1203584A1 (de) 2000-10-13 2002-05-08 M.D.M. S.r.l. Cholinerger Vorläufer (insbesondere Cholin-alfoscerat) assoziiert mit einem Acetylcholinesterase Inhibitor (wie z.B. Rivastigmin, Donepezil)
US6500972B2 (en) * 2001-01-03 2002-12-31 Chinese Petroleim Corp. Synthesis of TMBQ with transition metal-containing molecular sieve as catalysts
US6500955B1 (en) * 2001-02-02 2002-12-31 National Institute Of Pharmaceutical Education And Research One pot synthesis of [2,8-Bis (trifluoromethyl)-4-quinolinyl]-2-pyridinylmethanone, a mefloquine intermediate
EP1377640B1 (de) * 2001-04-09 2017-05-17 FUJIFILM Corporation Azoverbindungen und verfahren zur herstellung derselben und neue zwischenverbdindungen zur herstellung von azoverbindungen
HRP20030791B1 (en) * 2001-04-12 2006-06-30 F. Hoffmann - La Roche Ag DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS mGluR2 ANTAGONISTS I
EP1379511B1 (de) * 2001-04-12 2005-07-20 F. Hoffmann-La Roche Ag DIHYDRO-BENZO (b) (1,4) DIAZEPIN-2-ON-DERIVATE ALS MGLUR2 ANTAGONISTEN
US6949542B2 (en) * 2002-02-06 2005-09-27 Hoffman-La Roche Inc. Dihydro-benzo[b][1,4]diazepin-2-one derivatives

Also Published As

Publication number Publication date
EP1651234B1 (de) 2007-09-26
SI1651234T1 (sl) 2008-02-29
CN1856312A (zh) 2006-11-01
KR100764330B1 (ko) 2007-10-05
DE602004009195T2 (de) 2008-06-26
RU2357734C2 (ru) 2009-06-10
AU2004262897B9 (en) 2009-12-17
DE602004009195D1 (de) 2007-11-08
PL1651234T3 (pl) 2008-02-29
US7235547B2 (en) 2007-06-26
RU2006105721A (ru) 2007-09-10
HRP20070552T3 (en) 2008-05-31
DK1651234T3 (da) 2008-01-28
IL173131A0 (en) 2006-06-11
AU2004262897A1 (en) 2005-02-17
AU2004262897B2 (en) 2009-08-20
PT1651234E (pt) 2007-12-28
NZ544719A (en) 2009-04-30
TW200524614A (en) 2005-08-01
AR045926A1 (es) 2005-11-16
US20050049243A1 (en) 2005-03-03
JP2007504096A (ja) 2007-03-01
MXPA06000705A (es) 2006-04-11
NO20060328L (no) 2006-02-17
KR20060037404A (ko) 2006-05-03
IL173131A (en) 2010-12-30
WO2005014002A1 (en) 2005-02-17
ZA200600693B (en) 2007-05-30
CA2532347C (en) 2012-03-27
MY138394A (en) 2009-05-29
BRPI0412919A (pt) 2006-09-26
EP1651234A1 (de) 2006-05-03
ES2293287T3 (es) 2008-03-16
CO5640124A2 (es) 2006-05-31
JP5005343B2 (ja) 2012-08-22
CA2532347A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
DE602004009195D1 (de) Kombination eines mglur2 antagonists und eines ache inhibitors zur behandlung von akuten und/oder chronischen neurologischen krankheiten
DE60324777D1 (de) Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten
DE602004010407D1 (de) Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
EP2073811A4 (de) Kinasehemmer zur behandlung myleoproliferativer und anderer proliferativer erkrankungen
ATE513550T1 (de) Verwendung eines ibat-hemmers zur behandlung oder vorbeugung von verstopfung
EP1931691A4 (de) Odkase-inhibitoren zur behandlung von malaria
DE602004020660D1 (de) Pyrazolylderivative in form von arzneimitteln zur behandlung von akuten oder chronischen neuronalen regressionen
EP2148683A4 (de) Verfahren zur sicheren und wirksamen behandlung und prävention von sekundärer hyperparathyreose bei chronischer nierenerkrankung
DE60221798D1 (de) Kombinationen von gallensäuresequestriermitteln und hemmern der sterolabsorption zur behandlung von kardiovaskulären indikationen
NO20082894L (no) Metode for behandling av kognitiv dysfunksjon
DE60134009D1 (de) Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose
EP1786428A4 (de) Pde5-hemmer-zusammensetzungen und verfahren zur behandlung von herzerkrankungen
EP1546285A4 (de) Nitrifikationshemmende behandlung von weideb den
ATE446754T1 (de) Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten
DE602004019576D1 (de) Zur behandlung von schmerzen geeignete piperazine
EP1905452A4 (de) Wirkstoff zur prävention oder behandlung von glaukomen
DE60224004D1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
DE602005010222D1 (de) Verwendung eines phenothiazin-derivats zur prävention und/oder behandlung von gerhörverlust
ATE429222T1 (de) Medikamente zur behandlung oder prävention fibrotischer krankheiten
ATE457725T1 (de) Kynurenine 3-hydroxylase inhibitoren zur behandlung von diabetes
ATE429221T1 (de) Medikamente zur behandlung oder prävention fibrotischer krankheiten
DE50301045D1 (de) Cmos-prozess-kompatible hoch-dk-oberflächenbeschichtung zur kapazitiven detektion und stimulation biologischer gewebe
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
SI1362590T1 (sl) Uporaba ciklobradina ali njegovih farmacevtsko sprejemljivih soli za zdravljenje ali preprečevanje
DE602004011275D1 (de) Zusammensetzungen und Verfahren zur Behandlung von Fettleibigkeit

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1651234

Country of ref document: EP